Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Marti, Franziska ^a   Vollenweider, Peter ^b   Marques Vidal, Pedro Manuel ^a,c   Mooser, Vincent ^b   Waeber, Gérard ^b   Paccaud, Fred ^a   Bochud, Murielle ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; URIC ACID;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PHYSIOLOGY; QUESTIONNAIRE; RISK; SWITZERLAND; URINE;

ADULT; AGED; ALBUMINURIA; CAUSALITY; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; RISK; SWITZERLAND; URIC ACID;

EID: 80053382219     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-733     Document Type: Article

References (42)

1. Association between serum homocysteine and markers of impaired kidney function in adults in the United States.[see comment]. Francis ME, Eggers PW, Hostetter TH, Briggs JP, Kidney International 2004 66 303 312 10.1111/j.1523-1755.2004.00732.x 15200438 (Pubitemid 38870107)
2. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, et al. Circulation 2000 101 1506 1511 10747342 (Pubitemid 30180885)
3. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M, Mayo Clin Proc 2008 83 1203 1212 10.4065/83.11.1203 18990318
4. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, et al. J Am Soc Nephrol 2005 16 255 260 15563562 (Pubitemid 43073180)
5. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. J Nutr 2006 136 1731S 1740S 16702348 (Pubitemid 43765389)
6. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Hypertension 2003 42 1050 1065 10.1161/01.HYP. 0000102971.85504.7c 14604997 (Pubitemid 37413751)
7. Clinical epidemiology of cardiovascular disease in chronic renal disease. Foley RN, Parfrey PS, Sarnak MJ, Am J Kidney Dis 1998 32 112 S119 10.1053/ajkd.1998.v32.pm9820470 9820470
8. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. J Biol Chem 1997 272 17012 17017 10.1074/jbc.272.27.17012 9202015 (Pubitemid 27289806)
9. Homocysteine and atherothrombosis. Welch GN, Loscalzo J, N Engl J Med 1998 338 1042 1050 10.1056/NEJM199804093381507 9535670 (Pubitemid 28180407)
10. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, et al. Kidney Int 1998 54 203 209 10.1038/sj.ki.4495353 9648080 (Pubitemid 28288036)
11. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, et al. Arterioscler Thromb Vasc Biol 2001 21 74 81 10.1161/01.ATV.21.1.74 11145936 (Pubitemid 32061930)
12. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de LA, et al. Diabetologia 1998 41 684 693 10.1007/s001250050969 9662051 (Pubitemid 28261404)
13. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Lanfredini M, Fiorina P, Peca MG, Veronelli A, Mello A, Astorri E, et al. Metabolism 1998 47 915 921 10.1016/S0026-0495(98)90344-4 9711985 (Pubitemid 28364607)
14. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Keane WF, Eknoyan G, Am J Kidney Dis 1999 33 1004 1010 10.1016/S0272-6386(99)70442-7 10213663 (Pubitemid 29214705)
15. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H, Lancet 1982 1 1430 1432 6123720 (Pubitemid 12123979)
16. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Int J Epidemiol 2004 33 189 198 10.1093/ije/dyh008 15075168 (Pubitemid 38500176)
17. Elevated uric acid increases the risk for kidney disease. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R, J Am Soc Nephrol 2008 19 2407 2413 10.1681/ASN.2008010080 18799720
18. Uric acid and long-term outcomes in CKD. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Am J Kidney Dis 2009 53 796 803 10.1053/j.ajkd.2008.12.021 19303683
19. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J Jr, Am J Clin Nutr 1996 64 587 593 8839504 (Pubitemid 26334238)
20. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, et al. Atherosclerosis 1995 114 175 183 10.1016/0021-9150(94)05481-W 7605386
21. Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D, Kidney Blood Press Res 2008 31 259 267 10.1159/000142725 18689992
22. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. BMC Cardiovasc Disord 2008 8 6 10.1186/1471-2261-8-6 18366642 (Pubitemid 351566647)
23. Validation of the Omron HEM-907 device for blood pressure measurement. El Assaad MA, Topouchian JA, Darne BM, Asmar RG, Blood Press Monit 2002 7 237 241 10.1097/00126097-200208000-00006 12198340
24. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. Circulation 2006 114 1083 1087 10.1161/CIRCULATIONAHA.106.177321 16894032 (Pubitemid 44358886)
25. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. Ann Intern Med 2003 139 137 147 12859163
26. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
27. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. Nat Genet 1995 10 111 113 10.1038/ng0595-111 7647779
28. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, et al. Nat Genet 2008 40 768 775 10.1038/ng.140 18454148 (Pubitemid 351748863)
29. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD, Lancet 2005 365 224 232 15652605 (Pubitemid 40138016)
30. Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Jamison RL, Shih MC, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, et al. Am J Kidney Dis 2009 53 779 789 10.1053/j.ajkd.2008.12.023 19272686
31. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Wald DS, Law M, Morris JK, BMJ 2002 325 1202 10.1136/bmj.325. 7374.1202 12446535
32. Association of polymorphism of methylene-tetrahydro-folate-reductase with urinary albumin excretion rate in type 1 diabetes mellitus but not with preeclampsia, retinopathy, and preterm delivery. Lauszus FF, Gron PL, Klebe JG, Acta Obstet Gynecol Scand 2001 80 803 806 10.1034/j.1600-0412.2001.080009803.x 11531629 (Pubitemid 32846381)
33. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, et al. Diabetes Res Clin Pract 2007 75 99 106 10.1016/j.diabres.2006.05.018 16828193 (Pubitemid 44856026)
34. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Neugebauer S, Baba T, Watanabe T, Lancet 1998 352 454 9708760 (Pubitemid 28362798)
35. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Noiri E, Taguchi J, Nakao A, Fujita T, Diabetes Care 2000 23 260 10868847 (Pubitemid 30071039)
36. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Sun J, Xu Y, Zhu Y, Lu H, Diabetes Res Clin Pract 2004 64 185 190 10.1016/j.diabres.2003. 10.022 15126006 (Pubitemid 38582010)
37. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Boger CA, Stubanus M, Haak T, Gotz AK, Christ J, Hoffmann U, et al. Nephrol Dial Transplant 2007 22 154 162 17005529 (Pubitemid 46050340)
38. Methylenetetrahydrofolate reductase and methionine synthase reductase gene polymorphisms and protection from microvascular complications in adolescents with type 1 diabetes. Wiltshire EJ, Mohsin F, Chan A, Donaghue KC, Pediatr Diabetes 2008 9 348 353 10.1111/j.1399-5448.2008.00374.x 18774994
39. Involvement of reactive oxygen species in kidney damage. Baud L, Ardaillou R, Br Med Bull 1993 49 621 629 8221027 (Pubitemid 23243834)
40. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Tanaka K, Okubo K, et al. Am J Kidney Dis 2004 44 437 445 15332216 (Pubitemid 39164620)
41. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
42. Smoking and plasma homocysteine. O'Callaghan P, Meleady R, Fitzgerald T, Graham I, Eur Heart J 2002 23 1580 1586 10.1053/euhj.2002.3172 12323157 (Pubitemid 35221562)